GI Cancer Trials

Gastro-intestinal (GI) cancer is the most common form of cancer in Australia. It affects more than 37,567 Australians each year and claims 50 lives every day. GI cancer includes cancers of the digestive system – oesophagus, stomach, liver, gallbladder and biliary tract, pancreas, large and small bowel, rectum and anus. Despite its prevalence, survival rates remain low: the chance of surviving five years after diagnosis is just 50%.

We’re working to change that.

By uniting a diverse network of brilliant clinicians, researchers, and community advocates, we deliver clinical trials that lead to better treatments, improved quality of life, and longer survival. Since 1991, we’ve conducted 90 research studies, giving more than 9,930 people access to promising new treatments, faster.

Clinical trials are how progress happens. They test whether new treatments work better than the current standard of care, and they’re essential to ensuring new therapies are safe, effective, and ready to be used more widely.

For patients, clinical trials can offer immediate access to the latest treatments and often improve both outcomes and quality of life. Running trials here in Australia means people can benefit from these advances up to five years earlier than if the trials were held overseas.

One of the biggest barriers to advancing GI cancer research is a lack of funding. Community support is crucial. Your generosity helps us launch new clinical trials, give more people access to innovative treatments, and ultimately save lives.

There are many ways to get involved. Every action, big or small, brings us closer to a better future for people with GI cancer.